» Articles » PMID: 2866966

Acute Effect of Indenolol on Human Airways

Overview
Specialty Pharmacology
Date 1985 Jan 1
PMID 2866966
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Airways resistance and expiratory flow have been investigated in 6 healthy volunteers given single doses of indenolol, propranolol, atenolol and placebo in a randomized, double-blind, cross over study. The three active drugs significantly decreased the effort-induced rise in systolic pressure, and they also reduced the resting heart rate. The relative potency against exercise-tachicardia was propranolol greater than atenolol greater than indenolol. The double and triple product were significantly decreased, too, without any difference between the active treatments. After placebo or indenolol, an exercise-induced increase in the forced expiratory flow at low pulmonary volumes (MEF50 and MEF75) was observed. The two control beta-blockers caused a fall in exercise expiratory flow as compared to the resting values. The noncardioselective agent (propranolol) was more effective than the cardioselective compound (atenolol) in decreasing the expiratory flow. The mechanism of action of indenolol is discussed in the light of the lack of its acute effect on airways resistance.

Citing Articles

Wearable Activity Trackers and Physical Activity Levels Among Members of the Athens Medical Association in Greece.

Lampsas S, Marinos G, Lamprinos D, Theofilis P, Zakynthinos G, Gialamas I J Cardiovasc Dev Dis. 2024; 11(10).

PMID: 39452306 PMC: 11509063. DOI: 10.3390/jcdd11100336.


Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Wadworth A, Murdoch D, Brogden R Drugs. 1991; 42(3):468-510.

PMID: 1720383 DOI: 10.2165/00003495-199142030-00007.

References
1.
Decalmer P, Chatterjee S, Cruickshank J, Benson M, STERLING G . Beta-blockers and asthma. Br Heart J. 1978; 40(2):184-9. PMC: 482795. DOI: 10.1136/hrt.40.2.184. View

2.
Tachikawa S, Takenaka T . Pharmacological studies on 1-(7-indenyloxy)-3-isopropylaminopropan-2-Ol hydrochloride (YB-2), a new -adrenergic blocking agent. Arch Int Pharmacodyn Ther. 1973; 202(1):79-92. View

3.
Gayrard P, Orehek J, Grimaud C, CHARPIN J . Beta-adrenergic function in airways of healthy and asthmatic subjects. Thorax. 1975; 30(6):657-62. PMC: 470342. DOI: 10.1136/thx.30.6.657. View

4.
Simpson F . Practolol treatment in asthmatics. Lancet. 1971; 2(7736):1264-5. DOI: 10.1016/s0140-6736(71)90585-x. View

5.
Tanenaka T, Tachikawa S . -adrenergic blocking and cardiovascular properties of a new compound, 1-(7-indenyloxy)-3-isopropylaminopropan-2-ol-hydrochloride (YB-2). Arzneimittelforschung. 1972; 22(11):1864-9. View